US 9,809,647 B2
Neutralizing anti-CCL20 antibodies
Toshio Imai, Kyoto (JP); James Bradford Kline, Morgantown, PA (US); Tetsu Kawano, Kobe (JP); Luigi Grasso, Bryn Mawr, PA (US); Yoshimasa Sakamoto, Nishinomiya (JP); Jared Spidel, Downingtown, PA (US); Miyuki Nishimura, Kobe (JP); Kenzo Muramoto, Tsukuba (JP); and Tatsuo Horizoe, Moriya (JP)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
Filed on Aug. 3, 2015, as Appl. No. 14/816,989.
Application 13/924,433 is a division of application No. 13/300,352, filed on Nov. 18, 2011, granted, now 8,491,901, issued on Jul. 23, 2013.
Application 14/816,989 is a continuation of application No. 13/924,433, filed on Jun. 21, 2013, granted, now 9,133,273.
Claims priority of provisional application 61/415,614, filed on Nov. 19, 2010.
Prior Publication US 2016/0046707 A1, Feb. 18, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/24 (2013.01) [G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/521 (2013.01)] 7 Claims
 
1. A monoclonal anti-human CCL20 antibody or an antigen-binding portion thereof, whose heavy chain complementarity determining region 1 (CDR1), complementarity determining region 2 (CDR2), and complementarity determining region 3 (CDR3) and whose light chain CDR1, CDR2, and CDR3 comprise the amino acid sequences of:
a) SEQ ID NOS: 60, 64, 67, 70, 73, and 75, respectively;
b) SEQ ID NOS: 60, 64, 67, 71, 73, and 75, respectively;
c) SEQ ID NOS: 77, 79, 67, 70, 73, and 75, respectively; or
d) SEQ ID NOS: 77, 79, 67, 71, 73, and 75, respectively;
wherein said monoclonal antibody or antigen-binding portion further comprises a detectable label.